193 related articles for article (PubMed ID: 37505161)
21. Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.
Becker O; Beaulaton C; Masliah-Planchon J; Servois V; Watson S
Eur J Cancer; 2021 Feb; 144():386-388. PubMed ID: 33358840
[No Abstract] [Full Text] [Related]
22. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
Liang Y; Li C; Liu Y; Tian L; Yang D
BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
[TBL] [Abstract][Full Text] [Related]
24. A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma.
Wang X; Katz S; Miura J; Karakousis G; Roshkovan L; Walker S; McNulty S; Ciunci C; Cengel K; Langer CJ; Marmarelis ME
PLoS One; 2022; 17(9):e0275187. PubMed ID: 36174024
[TBL] [Abstract][Full Text] [Related]
25. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
[TBL] [Abstract][Full Text] [Related]
26. [A case of malignant peritoneal mesothelioma diagnosed with laparoscopic biopsy].
Yagi Y; Maeda T; Yoshimitsu Y; Sakuma H
Gan To Kagaku Ryoho; 2014 Aug; 41(8):995-7. PubMed ID: 25132032
[TBL] [Abstract][Full Text] [Related]
27. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
28. Ocular melanoma in a patient successfully treated for diffuse malignant peritoneal mesothelioma: a case report.
Langlais S; Velazquez-Martin JP; Dubé P; Simpson ER; Leblanc G; Sideris L
World J Surg Oncol; 2012 May; 10():90. PubMed ID: 22613358
[TBL] [Abstract][Full Text] [Related]
29. Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation.
Peitl M; Seiwerth S; Bašić-Koretić M; Šantek F
Indian J Med Paediatr Oncol; 2017; 38(1):73-77. PubMed ID: 28469343
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R; Shimoi T; Sudo K; Noguchi E; Nagata Y; Sawada R; Takashima A; Boku N; Yonemori K
BMC Cancer; 2021 Mar; 21(1):294. PubMed ID: 33743636
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy].
Costamagna D; Scuderi S; Vaira M; Barone R; De Simone M
Tumori; 2003; 89(4 Suppl):40-2. PubMed ID: 12903541
[TBL] [Abstract][Full Text] [Related]
32. Malignant mesothelioma of the peritoneum as the cause of a paraneoplastic syndrome: detection by 18F-FDG PET.
Banayan S; Hot A; Janier M; Ninet J; Zurlinden O; Billotey C
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):751. PubMed ID: 16607545
[No Abstract] [Full Text] [Related]
33. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
34. Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature.
Talerman A; Montero JR; Chilcote RR; Okagaki T
Am J Surg Pathol; 1985 Jan; 9(1):73-80. PubMed ID: 3970301
[TBL] [Abstract][Full Text] [Related]
35. [A Case of Malignant Peritoneal Mesothelioma Treated with Cisplatin and Pemetrexed].
Sone T; Omori S; Hayashi K; Yamato H; Ohira K; Kondo N; Takagi Y; Kato K
Gan To Kagaku Ryoho; 2018 Jun; 45(6):993-995. PubMed ID: 30026430
[TBL] [Abstract][Full Text] [Related]
36. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
[TBL] [Abstract][Full Text] [Related]
37. [A difficult to treat case of malignant peritoneal mesothelioma with peritoneal metastasis].
Ojima T; Takai Y; Yamazaki K; Kamata T; Kanno M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2463-5. PubMed ID: 24394145
[TBL] [Abstract][Full Text] [Related]
38. Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.
Vlasveld LT; Taal BG; Kroon BB; Gallee MP; Rodenhuis S
Cancer Chemother Pharmacol; 1992; 29(5):405-8. PubMed ID: 1551180
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
40. Diffuse malignant peritoneal mesothelioma.
Shih CA; Ho SP; Tsay FW; Lai KH; Hsu PI
Kaohsiung J Med Sci; 2013 Nov; 29(11):642-5. PubMed ID: 24183360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
